Clinical Trial Update: A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing GSK2118436 (dabrafenib) to dacarbazine in previously untreated BRAF mutation-positive advanced or metastatic melanoma; trial completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• GSK2118436 (dabrafenib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-05-16